Novavax has shared positive preliminary results from a real-world study of its JN.1-adapted COVID-19 vaccine. The SHIELD-Utah ...

Novavax (NVAX) closed the most recent trading day at $6.01, moving +0.17% from the previous trading session. This change outpaced the S&P 500's 2.36% loss on the day. Elsewhere, the Dow saw a ...

The U.S. federal government's "covid.gov" website now redirects to a White House page offering up the unproven theory that ...

Shares of Novavax Inc. NVAX shed 3.23% to $6.00 Thursday, on what proved to be an all-around dismal trading session for the ...

Shares of several vaccine makers soared after reports suggest that the Biden administration is in discussions with Moderna MRNA and Pfizer PFE to set up a possible vaccine program aimed at preventing ...

According to TipRanks, Stranahan is an analyst with an average return of -15.0% and a 32.39% success rate. Stranahan covers the Healthcare sector, focusing on stocks such as Candel Therapeutics, ...

Yesterday, Novavax presented early data from a real-world study suggesting that its 2024-25 protein-based COVID-19 vaccine ...

Novavax (NVAX) closed the most recent trading day at $6.39, moving -0.31% from the previous trading session. This move lagged the S&P 500's daily loss of 0.17%. Meanwhile, the Dow experienced a drop ...

As in previous studies, the SHIELD study found health care workers who received the Novavax vaccine reported significantly ...